|
|
Article: OTHER NEWS TO NOTE.
- Article from:
- BIOWORLD Today
- Article date:
- April 4, 2000
CopyrightCOPYRIGHT 2000 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abgenix Inc., of Fremont, Calif., initiated its first Phase II clinical trial with ABX-IL8. The multi-center, placebo-controlled trial is expected to enroll 90 patients with moderate to severe psoriasis. An interim review of data is possible by the end of this year. Future additional Phase II trials of the drug are being evaluated in psoriasis and other indications, such as rheumatoid arthritis and cancer.
Adenosine Therapeutics LLC, of Charlottesville, Va., said it signed a licensing agreement for its potent coronary vasodilator compounds, ATL-146e and ATL-193, with DuPont Pharmaceuticals Co., of Wilmington, Del. DuPont has obtained a worldwide license for the ...